Ronald MD - Rxsight CEO CoPresident
| RXST Stock | USD 24.55 0.30 1.21% |
CEO
Ronald MD is CEO CoPresident of Rxsight
| Age | 62 |
| Address | 100 Columbia, Aliso Viejo, CA, United States, 92656 |
| Phone | 949 521 7830 |
| Web | https://www.rxsight.com |
Rxsight Management Efficiency
The company has return on total asset (ROA) of (0.0919) % which means that it has lost $0.0919 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1243) %, meaning that it created substantial loss on money invested by shareholders. Rxsight's management efficiency ratios could be used to measure how well Rxsight manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.08 in 2025. Return On Capital Employed is likely to drop to -0.13 in 2025. Change To Liabilities is likely to gain to about 6.6 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 17.4 M in 2025.Similar Executives
| Found 14 records | CEO Age | ||
| Karen Zaderej | Axogen Inc | 63 | |
| Roger Susi | Iradimed Co | 72 | |
| Michael Stewart | STRATA Skin Sciences | 68 | |
| Charles II | Apyx Medical | 58 | |
| Nadim Yared | CVRx Inc | 56 | |
| Kevin Hykes | CVRx Inc | 59 | |
| Dolev Rafaeli | STRATA Skin Sciences | 61 | |
| Joel Becker | Neuropace | 57 | |
| Sunny Sanyal | Varex Imaging Corp | 61 | |
| Steven Williamson | Pulmonx Corp | 52 | |
| Glendon French | Pulmonx Corp | 62 | |
| Albert DaCosta | Paragon 28 | 52 | |
| Mark Throdahl | Orthopediatrics Corp | 74 | |
| Massimo Calafiore | Orthofix Medical | 52 | |
Management Performance
| Return On Equity | -0.12 | ||||
| Return On Asset | -0.0919 |
Rxsight Leadership Team
Elected by the shareholders, the Rxsight's board of directors comprises two types of representatives: Rxsight inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rxsight. The board's role is to monitor Rxsight's management team and ensure that shareholders' interests are well served. Rxsight's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rxsight's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matt Haller, Chief Officer | ||
| Alex Huang, Investor Relations | ||
| Oliver Moravcevic, Vice Relations | ||
| Ilya Goldshleger, CoPresident Officer | ||
| Patrick Cullen, Executive Operations | ||
| Scott Gaines, Executive Operations | ||
| Ronald MD, CEO CoPresident | ||
| Caroline Vaughn, Vice Resources | ||
| Steve Everly, Senior America | ||
| Rebecca Williston, Vice Finance | ||
| Eric Weinberg, CoPresident Officer | ||
| Roy Freeman, Senior Relations | ||
| Maureen OConnell, Executive Affairs | ||
| Shelley Thunen, CoPresident Officer |
Rxsight Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rxsight a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.12 | ||||
| Return On Asset | -0.0919 | ||||
| Profit Margin | (0.20) % | ||||
| Operating Margin | (0.21) % | ||||
| Current Valuation | 781.26 M | ||||
| Shares Outstanding | 40.49 M | ||||
| Shares Owned By Insiders | 5.05 % | ||||
| Shares Owned By Institutions | 91.19 % | ||||
| Number Of Shares Shorted | 2.41 M | ||||
| Price To Earning | 42.55 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Rxsight Stock Analysis
When running Rxsight's price analysis, check to measure Rxsight's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rxsight is operating at the current time. Most of Rxsight's value examination focuses on studying past and present price action to predict the probability of Rxsight's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rxsight's price. Additionally, you may evaluate how the addition of Rxsight to your portfolios can decrease your overall portfolio volatility.